Acute Myeloid Leukemia: Novel Therapeutic Agents and Clinical Trials

Dear Colleagues,

In recent years, there has been a dramatic improvement in our understanding of acute myeloid leukemia (AML), with the discovery of many possible targets for therapeutic intervention. First of all, AML can no longer be considered as one entity. Instead, it is now regarded as a group of clinically similar disorders caused by quite distinct molecular alterations. The diversity of AML decreases the chances of developing therapies that are similarly effective across all types of AML. However, simultaneously, it opens an avenue for exploring this diversity and identifying several previously unknown molecules that are involved. They, in turn, may serve as targets and, in other words, be "druggable". The first type of AML with distinct management was acute promyelocytic leukemia, which is susceptible to tretinoic acid and arsenic trioxide. This was followed by FLT-3 mutant leukemia, where several active compounds were identified, and then IDH-1 and IDH-2 mutant leukemia, also with targeted drugs available. This list will continue to grow, and the aim of the proposed Special Issue is, on one hand, to summarize the knowledge on the aforementioned treatments and, on the other hand, to review existing knowledge concerning compounds in preclinical research and in clinical trials. AML in all its forms remains one of the biggest challenges to contemporary hematology and requires innovative approaches to achieve control.

Prof. Dr. Wieslaw W. Jedrzejczak
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.